Peter J. Langecker, M.D., Ph.D

Chief Executive Officer

Dr. Langecker was named Chief Development Officer, and then Chief Executive Officer, in 2009, and has more than 20 years of experience in successfully developing both drugs and biological products. Among the approved oncology drugs he has had a role in developing are FORMESTAN®, LENTARON®, TEMODAL®, INTRON-A® for adjuvant treatment of melanoma, EULEXIN® and BEXXAR®. Dr. Langecker joins OXiGENE from DURECT Corporation where he served as Chief Medical Officer. He received his medical degree and his doctorate in medical sciences from the Ludwig-Maximilians University in Munich and trained in hematology and oncology. Dr. Langecker was formerly based in Switzerland where he supported development of early aromatase inhibitors and worked on a variety of other products for CIBA GEIGY (now Novartis). His industry experience in the United States includes key roles with Schering-Plough, Coulter Pharmaceuticals, SUGEN, Inc., and Intarcia Therapeutics.